Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: FDA Approves First Fluorescent Imaging Agent For Ovarian Cancer

Executive Summary

On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

You may also be interested in...



News We’re Watching: SALSA Reintroduced, FDA Approves Abbott Valve, Metallic Implant Study

A bill aimed at preventing laboratory reimbursement cuts has been reintroduced in the US Congress. Additionally, an Abbott valve landed FDA approval, On Target Labs reported trial results, and the FDA warned that dental palate expanders may pose health risks to adults.

News We’re Watching: Free COVID-19 Tests, Edwards Antitrust Investigation, McKinsey Calls For Medtech ‘Reinvention’

This week, the US government relaunched a program providing free COVID-19 tests and invested $600m in domestic test manufacturing; the European Commission revealed an antitrust investigation of Edwards LifeSciences; and a consulting firm report said the medtech industry should make big changes to address investor skepticism.

Minute Insight: Enovis Buys Lima To Create Billion-Dollar Recon Business

Enovis has agreed to buy Italian orthopedic implant manufacturer Lima from a private equity firm for €800m – about $845m. The deal will expand Enovis’ presence in the fast-growing international extremities market and improve its manufacturing and innovation facilities.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel